A meeting on the transition of the Republic of Kazakhstan’s healthcare system to Level III maturity was held in Astana. The event was attended by Kunsulu Zakarya, Advisor to the President of the Republic of Kazakhstan on Science and Innovation, as well as representatives of the Ministry of Healthcare and scientific organizations.

The meeting emphasized the importance of integrating scientific developments into healthcare and strengthening the applied focus of scientific activities. Participants discussed the steps required to align the national regulatory system with the requirements of the third level of maturity according to the classification of the World Health Organization (WHO).

Presidential Advisor Kunsulu Zakarya noted that the state considers the development of science as one of its key priorities, and that today it is especially important for the results of scientific research to find practical application and contribute to addressing the sector’s priority tasks.

Informative presentations on the priority areas of domestic science development were delivered by the leadership and leading specialists of the National Center for Biotechnology (NCB).
Arman Abeev, Director General of the NCB, presented the organization’s vision for further development, focusing on expanding research infrastructure, technology transfer, and introducing science-intensive products into practical healthcare.

Alexander Shustov, PhD in Biology, Head of Laboratory, presented the prospects for the application of CAR-T therapy — an innovative approach to treating hematological malignancies using chimeric antigen receptors.

Elena Zholdybayeva, PhD in Biology, Associate Professor, Head of Laboratory, shared current projects in human genetics and biotechnology aimed at developing personalized medicine and molecular approaches in healthcare.

Aralbek Rsaliev, Deputy Director General for Science and Technology of the National Holding “QazBioPharm,” noted that achieving Level III maturity of the regulatory system will open new opportunities for accelerated registration, international recognition, and access of domestic products to foreign markets.

The Holding is ready to support this goal — from developing its internal quality system and improving production processes in accordance with GMP requirements to digitalization and expanding interaction with regulatory authorities.

The Holding views the transition to Level III maturity as an important step in building a modern and competitive healthcare system in the Republic of Kazakhstan.